Environmental

R&D intensity of 8.5% of revenue suggests some process and product optimization focus, but peers in specialty pharma often disclose broader environmental targets and metrics.

Negative gross margin indicates limited operating efficiency, which can constrain funding for environmental compliance and upgrades relative to better-capitalized peers.

Very low debt-to-equity and negative net debt reduce balance-sheet pressure, supporting environmental investment capacity versus more leveraged peers.

No stock-based compensation burden lowers incentive-related dilution, but it does not materially differentiate environmental positioning from peers with stronger disclosure and targets.

Social

R&D spending at 8.5% of revenue can support product quality and patient-focused innovation, though peers typically provide clearer evidence on access and safety outcomes.

Zero stock-based compensation reduces pay-related stakeholder concerns, but it is a weaker social differentiator than peer disclosures on workforce retention and training.

Negative gross margin may limit resources for employee development and quality systems, leaving social resilience less robust than better-margin peers.

Limited leverage supports continuity of operations and supplier relationships, but the social profile remains average without stronger disclosure on labor and product stewardship.

Governance

Zero stock-based compensation suggests restrained dilution and simpler incentive design, which is cleaner than many peers with heavier equity compensation.

Debt-to-equity of 0.10 indicates conservative capital structure, reducing creditor pressure and governance complexity versus more levered peers.

Negative net debt provides liquidity flexibility, but governance strength remains only moderate because disclosure on board independence and controls is not provided.

R&D intensity shows some capital allocation discipline, yet peers with stronger governance typically pair this with more transparent oversight and risk reporting.

Overall Score

CPHI’s ESG positioning is broadly average versus peers, with balance-sheet conservatism helping, but limited disclosure and weaker operating efficiency cap relative strength.

Score Driver: Conservative Leverage Supports ESG Resilience, But Sparse Peer-Level ESG Disclosure Prevents A Stronger Relative Assessment.